Ocugen Appoints Rita Johnson-Greene to Chief Monetary Officer – Worldwide Dispatch

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Firm) (NASDAQ: OCGN), a pioneering biotechnology chief in gene therapies for blindness illnesses, at the moment introduced the appointment of Rita Johnson-Greene as Chief Monetary Officer (CFO).

“Mrs. Johnson-Greene’s numerous background throughout quite a lot of strategic roles at organizations representing many sides of the trade make her well-suited to function Ocugen’s CFO,” mentioned Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We look ahead to her management as we enter right into a transformative time at Ocugen, starting with the submission of the primary of three Biologics License Purposes (BLAs) this yr.”

Mrs. Johnson-Greene has greater than 20 years of healthcare expertise. She most just lately served as Chief Working Officer on the Alliance for Regenerative Drugs (ARM) the place she led ARM’s operations, finance, and world enlargement initiatives to advance the event of engineered cell therapies and genetic medicines and promote entry for all sufferers. Previous to her function at ARM, she was the Vice President of Gross sales and Certified Remedy Facilities (QTC) at Genetix Biotherapeutics (previously referred to as bluebird bio), the place she constructed and scaled pre-commercial U.S. gross sales and QTC operations groups to assist the launch of the ZYNTEGLO™ and SKYSONA™ gene remedy manufacturers. Mrs. Johnson-Greene additionally held senior management positions at Spark Therapeutics and supported the launch of LUXTERNA®. Beforehand, she held roles in finance, industrial operations, and gross sales in each North and South America for AstraZeneca. Mrs. Johnson-Greene started her profession in strategic consulting with Accenture’s technique apply.

“I’m excited to affix Ocugen and consider within the potential of the Firm’s novel modifier gene remedy platform to handle unmet medical wants that also exist for main blindness illnesses,” mentioned Mrs. Johnson-Greene. “Having been within the cell and gene remedy area for a few years, I perceive the distinctive enterprise wants required to function effectively and drive future success.”

Mrs. Johnson-Greene earned her MBA in Finance and Strategic Administration from The Wharton College on the College of Pennsylvania, and her undergraduate diploma in Electrical Pc Engineering from Drexel College. She serves on the Drexel College Biomed Dean’s Government Advisory Council and is a visitor lecturer for biomedical graduate college students. 

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology chief in gene therapies for blindness illnesses. Our breakthrough modifier gene remedy platform has the potential to handle vital unmet medical want for big affected person populations by way of our gene-agnostic strategy. In contrast to conventional gene therapies and gene enhancing, Ocugen’s modifier gene therapies handle your complete illness—complicated illnesses which can be probably attributable to imbalances in a number of gene networks. At present we’ve applications in growth for inherited retinal illnesses and blindness illnesses affecting thousands and thousands throughout the globe, together with retinitis pigmentosa, Stargardt illness, and geographic atrophy—late stage dry age-related macular degeneration. Uncover extra at www.ocugen.com and observe us on X and LinkedIn.

Cautionary Be aware on Ahead-Wanting Statements
This press launch accommodates forward-looking statements throughout the which means of The Non-public Securities Litigation Reform Act of 1995, that are topic to dangers and uncertainties. We could, in some instances, use phrases similar to “predicts,” “believes,” “potential,” “proposed,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “could,” “may,” “would possibly,” “will,” “ought to,” or different phrases that convey uncertainty of future occasions or outcomes to establish these forward-looking statements. Such statements are topic to quite a few vital elements, dangers, and uncertainties which will trigger precise occasions or outcomes to vary materially from our present expectations. These and different dangers and uncertainties are extra totally described in our periodic filings with the Securities and Change Fee (SEC), together with the danger elements described within the part entitled “Danger Components” within the quarterly and annual stories that we file with the SEC. Any forward-looking statements that we make on this press launch communicate solely as of the date of this press launch. Besides as required by regulation, we assume no obligation to replace forward-looking statements contained on this press launch whether or not on account of new info, future occasions, or in any other case, after the date of this press launch.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com